This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Classification

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Three types of von Willebrand's disease are recognised on the basis of ristocetin activity and other tests:

  • type I, the the classic type described by von Willebrand in 1926, where the von Willebrand factor is functionally normal but present at low levels
  • type II, a broad spectrum of diseases in which bleeding time is prolonged in almost all cases. vWF levels may increase under some conditions - like stress or pregnancy, correcting the bleeding time
  • type IIa - both plasma and platelet samples lack the intermediate and high molecular weight vWF multimers; platelets do not aggregate with ristocetin
  • type IIb - plasma lacks the highest molecular weight vWF multimers; platelets aggregate in response to low dose ristocetin
  • type III is inherited as an autosomal recessive trait. Homozygous individuals have severe bleeding problems related to marked reduction of all von Willebrand's factor parameters and of Factor VIII

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.